A Single-arm Study of Gemcitabine, Cisplatin, and Nab-Paclitaxel as Neoadjuvant Therapy for Resectable Oncologically High-Risk IHCC in Korea

NCT04546828 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped problem of sponsor

Conditions

Intrahepatic Cholangiocarcinoma

Interventions

DRUG: Gemcitabine, Cisplatin, and Nab-Paclitaxe

Sponsor

Samsung Medical Center